Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Mycophenylate -- A Potential New Option

September 1999

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Mycophenylate (CellCept®) is an available prescription drug that may enhance the anti-HIV activity of abacavir (Ziagen®). Most data so far come from lab studies published by David Margolis and Robert Redfield of the Institute for Human Virology (headed by Robert Gallo). The team also has started human studies.

Mycophenylate is normally used to prevent rejection of kidney transplants. Mycophenylate suppresses production of guanosine, a key building block of DNA critical to the reproduction of HIV. Researchers reasoned that the drug would be most effective if paired with an antiviral that produced "false building blocks" resembling guanosine. They realized this meant abacavir, which mimics guanosine.

This model is similar to what happens when combining hydroxyurea with ddI, though studies suggest the mycophenylate/abacavir combination may be more potent and less toxic. More importantly, lab studies show the combination is highly active when used against abacavir-resistant virus.

A key question is whether the combination adds unacceptable toxicity or immune suppression, sometimes a problem with hydroxyurea + ddI. Based on lab data, however, it appears mycophenlyate can be used at doses two to ten times lower than those employed in normal application and still achieve high level anti-HIV effects.

Advertisement
These observations need to be confirmed in human studies, and the first have already begun. The simple two-drug combination is being given to advanced-stage patients who have failed all other therapies. Dosing employs 250mg of mycophenylate twice daily with the standard abacavir dose. The current dose of mycophenylate was chosen largely for convenience and lower doses may be tried in the future.

It is too early to recommend this for common use, but it builds upon a proven model and offers hope of a better treatment than hydroxyurea + ddI. Mycophenylate also has activity against hepatitis C virus and should also combine well with ribavirin, which is currently used in the treatment of hepatitis C. Mycophenylate should not be used with AZT or d4T as it is likely to negatively effect the activity of those drugs.



Drug Identification Chart

Initials Generic Name Trade Name Manufacturer
Protease Inhibitors
AMP amprenavir Agenerase® Glaxo Wellcome
IDV indinavir Crixivan® Merck
NFV nefinavir Viracept® Agouron
SQVhgc saquinavir hard
gel capsule
Invirase® Hoffman-La Roche
SQVsgc saquinavir soft
gel capsule
Fortovase® Hoffman-La Roche
RTV ritonavir Norvir® Abbott Labs
NNRTIs
(Non-Nucleoside Reverse Transcriptase Inhibitors)
DLV delavirdine Rescriptor® Pharmacia & Upjohn
EFV efavirenz Sustiva® Dupont Pharma
NVP nevirapine Viramune® Boehringer Ingelheim
NARTIs
(Nucleoside Analog Reverse Transcriptase Inhibitors)
ABA abacavir Ziagen® Glaxo Wellcome
AZT zidovudine Retrovir® Glaxo Wellcome
AZT+3TC   Combivir® Glaxo Wellcome
ddC zalcitabine Hivid® Hoffman-La Roche
ddI didanosine Videx® Bristol-Myers Squibb
d4T stavudine Zerit® Bristol-Myers Squibb
3TC lamivudine Epivir® Glaxo Wellcome
NtARTIs
(Nucleotide Analog Reverse Transcriptase Inhibitors)
ADF adefovir Preveon® Gilead Sciences
Cellular Factor Inhibitors
HU hydroxyurea Hydrea® Bristol-Myers Squibb


Back to the Project Inform Perspective September 1999 contents page.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. Visit Project Inform's website to find out more about their activities, publications and services.
 
See Also
More Research on HIV/AIDS Treatment Strategies

Tools
 

Advertisement